公众号 / 文章泌尿生殖技术与安全PETCT

前列腺癌 PSMA PET 放射性药物实用指南

A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.
PubMed 文献 · AJR Am J Roentgenol · 2026-06-24

本文围绕 FDA 已批准的三种 PSMA 靶向 PET 放射性药物([68Ga]Ga-PSMA-11、[18F]DCFPyl、[18F]rhPSMA-7.3),比较其物理化学性质、清除途径、成像特征及供应物流差异。文章指出当前缺乏直接患者内比较证据,尚无任一药物在诊断效能上总体占优,旨在帮助放射科医生理解差异并指导临床选择。

要点

  • PSMA PET/CT 已成为部分前列腺癌适应证的标准治疗手段。
  • 不同 PSMA 药物清除途径不同,可能影响泌尿道旁或肝内病灶检出。
  • 目前证据未显示任一 PSMA 药物诊断效能总体占优,选择需综合实际因素。

核心结论

  • PSMA 靶向 PET 放射性药物之间不存在诊断效能的总体优劣。
  • 药物间的关键差异在于放射性核素理化性质、配体结构和清除途径,具有潜在临床影响。

研究设计与样本

  • 本文为 AJR 分子影像特别系列中的实用指南性质的专题文章。
  • 未报告系统检索策略或纳入排除标准。

关键影像表现/征象

  • PSMA 靶向放射性药物清除途径存在差别,以肾脏清除为主或以肝脏清除为主。

临床应用与阅片要点

  • 了解不同 PSMA 药物清除途径,有助于判断泌尿道邻近区域或肝内病灶的可评估性。
  • 治疗前评估中病灶摄取常以肝脏作为参考背景,药物清除差异可能影响此类比较。
  • 选择药物时需结合成像特征、供应物流和运营条件。
  • 解释图像时应知晓所用放射性药物的特定生理分布特点。

局限性

  • 目前不同 PSMA 靶向放射性药物之间直接患者内比较研究仍然有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Since the first FDA approval of a PSMA-targeted PET radiopharmaceutical ([68Ga]Ga-PSMA-11) in 2020, PSMA PET/CT has rapidly become the standard of care for certain indications in prostate cancer imaging. Subsequently, the FDA also approved [18F]DCFPyl and [18F]rhPSMA-7.3. Although these small-molecule agents share an amino acid binding domain specific to the PSMA molecule, they differ in key ways (e.g., radioisotope physical and chemical properties, ligand structure), with potential clinical implications regarding synthesis, distribution, and imaging characteristics. For example, differences in radiopharmaceutical clearance (predominantly renal vs hepatic) may impact the detection of lesions adjacent to the urinary tract or within the liver. This variability also influences pre-therapy assessment, during which lesion uptake is often compared to the liver as a reference. Direct intrapatient comparisons among PSMA-targeted radiopharmaceuticals remain limited, and current evidence suggests lack of overall superiority in diagnostic performance metrics for any individual radiopharmaceutical. Consequently, radiologists are left wondering why multiple PSMA-targeted radiopharmaceuticals are being developed, whether their distinct properties matter clinically, and ultimately which one to use. In this article, we explore clinically relevant similarities and differences of PSMA-targeted PET radiopharmaceuticals, highlighting their imaging characteristics, supply logistics, and other operational considerations, to guide their successful integration into clinical care.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Peacock, Franquet-Elia, Harris, et al. A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging. AJR Am J Roentgenol. 2026. PMID: 42340235. doi:10.2214/AJR.26.34730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。